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The neoplastic microenvironment has been recognized to play a critical role in the development of cancer. Although a large body
of evidence has established the importance of the cancer microenvironment, the manners of crosstalk between it and the cancer
cells still remains unclear. Emerging mechanisms of communication include microRNAs (miRNAs). miRNAs are small noncoding
RNA molecules that are involved in the posttranscriptional regulation of mRNA. Both intracellular and circulating miRNAs are
diﬀerentially expressed in cancer and some of these alterations have been correlated with clinical patient outcomes. The role of
miRNAs in the tumor microenvironment has only recently become a focus of research, however. In this paper, we discuss the
inﬂuence of miRNAs on the tumor microenvironment as it relates to cancer progression. We conclude that miRNAs are a critical
component in understanding invasion and metastasis of cancer cells.
1.Introduction
The belief that cancer cells are the sole dictators of their pro-
liferative, invasive and migratory abilities has been revised.
In its place is the view that the six hallmarks of cancer
cells, namely self-suﬃciency in growth signals, insensitivity
to antigrowth signals and self-renewal, evasion of apoptosis,
limitless replication potential, angiogenesis, invasion and
metastasis, result from heterotypic signaling of cancer cells
with its microenvironment [1]. Carcinoma progression and
prognosis are dependent on the interaction of cancer
epithelial cells with, and the recruitment of, tumor stroma,
immune cells, and vascular networks as well as the alteration
of the extracellular matrix [ECM] components (reviewed in
[2–4]).
How do cancer cells inﬂuence normal cells to abandon
their homeostatic activities and instead support the neo-
plastic nature of the tumor? Obviously, there must be some
methodofcommunicationbetweenthecancercellsandtheir
microenvironment. The dynamic crosstalk between cancer
cells and normal cells in the microenvironment is a crucial
point in the progression of disease. One manner of cell-
cell communication is through the secretion of molecules
and paracrine signaling. Molecules of secretion are no longer
limited to cytokines, chemokines, growth factors, and other
protein molecules but now include miRNA species. MiRNAs
are pleiotropic regulators of gene expression that regulate
various normal cellular processes as well as play a role in
disease progression, especially cancer. Some intracellular and
circulatingmiRNAspeciesaredysregulatedincancer,leading
to altered expression that in some cases has been correlated
with clinical outcomes for patients. Furthermore, a number
of recent studies have investigated the use of miRNAs as
noninvasive biomarkers for cancer diagnosis and prognosis.
However, the understanding of the cellular consequences
in the microenvironment of these diﬀerentially expressed
miRNAs is just beginning to be elucidated. In this paper, we
will speciﬁcally focus on carcinomas and miRNA regulation
of the associated microenvironments including the tumor
stroma, ECM components, and hypoxia.2 Molecular Biology International
Table 1: miRNA regulation in the tumor microenvironment.
miRNA Up- or downregulated Tumor microenvironment Tumor entity Reference
miR-16 Up CAF Bladder [11]
miR17/20 Down CAF Breast [30]
miR-21 Up ECM, Hypoxia Bile duct, breast, glia [36–38, 42]
miR-29b Up CAF Endometrial [18]
miR-29c Down ECM Nasophayngeal [40]
mirR-31 Down CAF Endometrial [18]
miR-143 Down CAF Bladder [11]
miR-145 Down CAF Bladder [11]
miR-146a Up CAF Endometrial [18]
miR-146b Down ECM Glia [39]
miR-320 Up CAF Bladder [11]
miR-503 Up CAF Endometrial [18]
2.miRNAs andCancer-AssociatedFibroblasts
The tumor stroma is composed of a number of diﬀerent
cell types including ﬁbroblasts, myoﬁbroblasts, adipocytes,
endothelial cells, pericytes, and immune cells. The tumor
stroma is essential not only in the survival of neoplasms
but the ability of these tumors to evolve invasiveness and
metastatic ability. Early studies appeared to indicate that
cancer-associatedﬁbroblasts(CAF)alsoaccumulatedgenetic
mutations much like neoplastic cells [5–8]. However, further
research has revealed that mutations in CAFs are rare events
indicating that other manners of altering gene expression
proﬁles in these cells must exist [9, 10]. A possible emerging
mechanism for the control of gene expression within the
tumor stroma by the cancer epithelium is the diﬀerential
expression and transfer of miRNA species (summarized in
Table 1).
A recent bladder cancer study has identiﬁed speciﬁc
miRNA proﬁles in CAFs [11]. Five independent ﬁbroblast
cell lines were established from invasive bladder cancer and
compared to normal bladder and foreskin ﬁbroblasts in a
miRNA microarray and validated in quantitative polymerase
chain reaction (qPCR) assays. These studies observed an
increase in miR-16 and miR-320 in CAFs in comparison to
normal bladder ﬁbroblasts. Surprisingly, miRNAs such as
miR-16 and miR-320 have been indicated to function in a
tumorsuppressormannerandshowntobedownregulatedin
certain cancers. The low expression of miR-16 and miR-320
in colorectal and pancreatic cancers [12, 13]i sb e l i e v e dt ob e
involved in cell proliferation [14]. The identiﬁcation of these
upregulated miRNAs in CAFs may indicate an initial com-
pensatory response by the CAFs in an attempt to block cel-
lular proliferation. Alternatively, it is possible that the upreg-
ulated miRNAs in CAFs facilitate tumor survival or progres-
sion.Additionalinvestigationsarenecessarytodeterminethe
potential consequences of miRNAs upregulated in one cell
population and downregulated in another within a tumor.
In contrast to the upregulated miRNAs, miR-143 and
miR-145 are downregulated in CAFs compared to foreskin
ﬁbroblasts. There was no signiﬁcant decrease in miR-143
and miR-145 between CAFs and normal bladder ﬁbroblasts,
however, although a trend was reported. MiR-143 and miR-
145arelocatedonchromosome5approximately1.3kbapart
andaremostlikelytranscribedasacluster;therefore,itisnot
surprising that similar trends are observed. Previous studies
in bladder cancer have shown decreased levels of miR-145
correlated with a decrease in apoptotic ability suggesting that
adecreaseinmiR-145inCAFsmayalsocontributetoevasion
of apoptosis in the microenvironment [15–17]. A similar
correlation with miR-143 has not been reported.
AnotherstudylookingattendiﬀerentCAFcelllinesfrom
endometrial cancers identiﬁed eleven diﬀerentially expressed
miRNAs in the CAFs in comparison to normal ﬁbroblasts
[18]. Of these eleven miRNAs identiﬁed in microarrays,
ﬁve were validated as statistically signiﬁcant in qPCR. These
included increased expression of miR-503 and miR-424,
which are present in a cluster of miRNAs found on chro-
mosomal location Xq26.3. Other upregulated miRNAs were
miR-29b and miR-146a. One miRNA, miR-31, was shown to
be downregulated in 9 out of 10 CAF cell lines. In addition
to qPCR validation of miRNA species, these ﬁve miRNAs
were shown to have signiﬁcant negative correlation with
their targets genes in microarray analysis of total RNA from
CAFs. For miR-31, 39 targets were identiﬁed as predicted
upregulated proteins in these cell lines, while for the miR-
503 and miR-424 cluster, 139 combined protein targets were
predicted to be downregulated. This correlation provides
additional evidence suggesting a functionally important role
of these miRNAs in CAF gene regulation.
Further analysis of miR-31 demonstrated that a number
of the predicted target genes for miR-31 are involved
in cellular movement. Proteins related to transcriptional
control found to be overexpressed included CCNJ, ELAVL1,
and ENY2. Genes involved in cellular movement and trans-
port correlated to lower levels of miR-31; they included
RHOBTB1 and CLASP2 involved in cytoskeletal organiza-
tion, VAMP4 in endosomal transport and STX12 in phago-
cytosis. A gene functioning in cellular transformation andMolecular Biology International 3
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Figure 1: Validated miRNAs and their gene targets in the microenvironment. In carcinoma cells, the loss of miR-17/20 is involved in
heterotypic signaling through the upregulation of cytokines IL-8 and CXCL-1 as well as plasminogen activators CK8 and α-ENO. In the
ECM, decreased amounts of miR-29c are found to result in an increase in collagens and laminin leading to alteration in ECM composition
conducive to invasion and migration. In addition, miR-146b is also decreased resulting in increased activity of MMP16 in ECM degradation.
In contrast, miR-21 levels are elevated resulting in inhibition of RECK and TIMP3, important metalloproteinase inhibitors. In the CAF,
although multiple miRNAs are diﬀerentially expressed, to date only a decrease in miR-31 has been validated to be directly involved in an
upregulation of SATB2 resulting in increased invasiveness and migration.
anchorage-independence, TACC2, is also a putative target
of miR-31. SATB2 demonstrated the greatest fold induction
of protein in these cells and is known to function in
chromatin remodeling and transcription regulation. Direct
evidence of SATB2 as a target for miR-31 was provided
through luciferase reporter assays (Figure 1). When condi-
tioned media from ﬁbroblasts overexpressing miR-31 was
incubated with endometrial carcinoma cells, their migration
and invasion potential was decreased although there was no
eﬀect on cell proliferation. The opposite was observed when
SATB2 was overexpressed in these cells indicative of a direct
role of miR-31 dysregulation in tumor stromal cells and the
progression of carcinomas. Taken together, these induced
genescanprovideCAFswithsomeofthehallmarksofcancer
cells such as anchorage-independence and enhanced cellular
movement and as such potentially serve as a means by which
CAFs act as support cells to the carcinoma.
However, there is some conﬂicting evidence on the role
of miR-31 in carcinomas. Upregulation of this miRNA was
foundincoloncancer[19–22]andsquamouscellcarcinomas
of the tongue [23]. Interestingly, in colon cancer studies not
only was miR-31 upregulated but this upregulation was
found to be associated with poorer clinical outcomes and
increased invasiveness [22]. Although this seems like a pote-
ntial contradiction for the role of miR-31 in tumor pro-
gression, an important variable between this study and that
of Aprilikova and colleagues is that the colon cancer study
evaluated the carcinoma cells and not the supporting tumor
stroma. Then again, there is some support for downregula-
tion of miR-31 in breast cancer [24, 25], gastric cancer [26],
and urothelial cancers [27]. In addition to the diﬀerences
in the type of cancer under investigation in these studies,
there are diﬀerences in methods used to retrieve and prepare
the tissues. Other details of the methods used in the various
studies could also have profound eﬀects on the data includ-
ing the choice of normalizer used for quantiﬁcation of the
qPCR assays [28, 29]. Such contradictory reports of miR-31
expression in cancer cells and the microenvironment further
highlight the importance of not only identifying diﬀerential
miRNA expression but the elucidation of validated target
genes.
The previously cited investigations identiﬁed miRNAs
that are dysregulated in CAFs and may contribute to tumor
progression. These studies did not look at the eﬀects of
miRNA signals from cancer epithelial cells on the tumor
microenvironment. A recent study by Yu and colleagues
has done just that [30]. Through their evaluation of three
highlyinvasivecelllinesandfournon-invasivecelllinesfrom
breast cancers, they have identiﬁed a miRNA cluster, miR-
17/20, involved in heterotypic signaling. When miR-17/20
is expressed in cancer cells, their ability for migration and
invasionissuppressed.Infact,whenconditionedmediafrom
miR-17/20 expressing cells was incubated with the highly
invasive cell line, MDA-MB-231, the ability of these cells to
migrate and invade across wounds or 3D collagen gels was
greatly inhibited. Further analysis of the role of miR-17/20 in
breast cancer cells determined that this miRNA cluster was
involved in the regulation of cellular secretion that altered
the cellular microenvironment. When miR-17/20 levels are
decreased, cancer cells increase secretion of cytokines IL-8
and CXCL-1 and proteins CK8 and alpha-ENO (Figure 1).
While secreted IL-8 and CXCL-1 have direct eﬀects on
neighboring cells through interaction with their respective
receptors, CK8 and alpha-ENO eﬀects are indirect as they
both act on plasminogen activation [31, 32]. The increase
in plasmin from plasminogen activation is an important
player in the process of ECM degradation that ultimately
facilitates migration and invasion. Moreover, an increase4 Molecular Biology International
in plasminogen activation has clinical importance in breast
cancer patients as it correlates with increased invasiveness
and poorer prognosis [33]. This is the ﬁrst line of evidence
to show that miRNAs are important in heterotypic signaling
in the microenvironment of the tumor and to correlate such
a role to clinical outcome.
This information taken together highlights the impor-
tance of determining where miRNA alterations originate
in tumor cells or the tumor stroma and establishing what
factors are responsible for these altered miRNA levels. Other
questions that deserve experimental attention are to evaluate
both primary and metastatic tumors to determine if miRNA
dysregulation is sustained or only associated with tumor
progression. In other words, are miRNA alterations that
we are currently detecting simply stills in an ever changing
landscape of tumor progression?
3. ECM Composition Inﬂuenced by miRNAs
The ECM is a key regulator in neoplasmic cell growth and
mobility. Alteration of the ECM to allow cell invasion,
migration, and angiogenesis is essential for a cancer’s ability
to move from a localized, primary site. It is well established
that signals such as increased matrix metalloproteinases
(MMPs) or decreased tissue inhibitors of metalloproteinases
(TIMPs) released into the tumor microenvironment play
a critical role in the reorganization of the ECM and thus
contribute to cancer metastatic ability. But what roles do
miRNAs play in MMP and TIMP expression?
MMPs function to degrade ECM proteins and process
bioactive molecules. In cancer progression, these functions
are important not only in the release of signaling molecules
from the ECM but in providing an avenue for migration,
invasion, and angiogenesis. MiR-21 has been shown to be
a major player in such migration and invasion in multiple
cancers including gliomas, cholangiocarcinomas, and breast
cancers [24, 34–37]. In gliomas, miR-21 levels have been
correlatedwithhigher-gradetumorsincludingglioblastomas
[38]. Targets for miR-21 in these cells have identiﬁed two
MMPS inhibitors, RECK and TIMP3, that inversely correlate
withthemiRNA(Figure 1).RECKisamembrane-anchorage
regulator while TIMP3 is an ECM-bound protease inhibitor.
When these proteins are downregulated in the presence of
miR-21, there is a subsequent increase in MMP activity and
invasiveness of the glioma. In addition, TIMP3 has been pre-
viously shown to be proapoptotic so the loss of this inhibitor
also allows for the evasion of apoptosis. Supporting evidence
for the ability of miR-21 to act as a direct inhibitor of TIMP3
function was substantiated by work by Selaru and colleagues
in human cholangiocarcinomas [36]. In contrast, although
their work has demonstrated that miR-21 was upregulated in
these tumors, it was not correlated with location or grade of
tumor. Nevertheless, there were signiﬁcant increases in miR-
21 expression and corresponding loss in TIMP3 message
in all tumor cell lines evaluated although a direct role in
invasiveness was not assessed in their study.
Although the previous studies did show a relationship
between miR-21 expression and TIMP3 levels, none showed
that miR-21 was directly inhibiting TIMP3 expression
through binding to predicted sites in the 3UTR of the tran-
script. Such conclusive evidence has recently been presented
in breast cancer cells [37]. Luciferase reporter assays using
the TIMP3 3UTR and miR-21 showed a signiﬁcant increase
in activity when breast cancer cell line MDA-MB-231 was
transfected with both species. In addition, their work further
conﬁrmed the association between miR-21 increases, loss
of TIMP3, and cell invasion both in culture and in lymph
node positive tissue specimens. Taken together, these studies
provide strong evidence for the role of miR-21 expression in
altering the ECM microenvironment of cancer cells allowing
invasion and metastasis.
Not surprisingly, other miRNAs are also currently being
identiﬁed as associated with ECM reorganization in relation-
ship to cancer. Much like miR-21, miR-146b has also been
demonstrated to play a role in glioma cell invasion [39].
However, miR-146b levels are found to be lower in glioblas-
toma cell lines. Thus, miR-146b does not work through the
suppression of ECM inhibitors but its loss allows the upre-
gulation of MMPs. Direct association of miR-146b with the
3UTR of MMP16 was shown to be linked with a loss of
MMP expression (Figure 1). When miR-146b levels are low,
migration and invasion are increased in several glioma cell
lines.
Another downregulated miRNA, miR-29c, was also
shown to alter the level of ECM protein in a highly inva-
sive cancer, nasopharyngeal carcinoma [40]. Experiments
using 31 tumor specimens identiﬁed miR-29c to have an
approximate5-folddecreaseinrelationtonormalspecimens.
Evaluation of potential targets for miR-29c revealed 10 ECM
component genes to be upregulated in these same tumors.
These genes included collagen types 3A1, 4A1, and 5A1
as well as laminin and thymine-DNA glycosylase. Direct
targeting of these genes was conﬁrmed through luciferase
activity. The ECM components mentioned above have been
implicated in cell migration and invasion by assisting in
matrix renewal allowing for tumor mobility. In addition,
increases in deposits of collagen and laminin have clinical
association with metastases in a variety of solid tumors [41].
TheabovedatailluminatetheextensiverolethatmiRNAs
are predicted to have on ECM composition and remodeling
during tumor progression. As evident, there are many
diﬀerent avenues including inhibition of TIMPs, activation
of MMPs, and alteration of ECM component secretion for
miRNAs to promote changes in the ECM that would be
beneﬁcial to the tumor. Primary tumors that have acquired
altered miRNA levels will utilize these changes to further
their destructive migratory and invasive properties.
4. The Role of miRNAs inthe HypoxicResponse
Thesurvivalofatumorisdependentonanhypoxicmicroen-
vironment, which increases its invasiveness and resistance
to drug treatment [34]. A signature of hypoxia-inducible
miRNAs has been identiﬁed which includes miR-21, 23a,
23b, 24, 26a, 26b, 27a, 30b, 93, 103, 103, 106a, 107, 125b,
181a, 181b, 181c, 192, 195, 210, and 213 [42]. Results from
other studies also found that miR-210, 30b, 93, and 181b
wereinducedunderhypoxicconditions[43–45].Inaddition,Molecular Biology International 5
miR-429, 498, 572, 563, 637, 628 were found to be induced
during hypoxia using a diﬀerent type of microarray [44].
Some miRNAs are downregulated under hypoxic conditions
including miR-122a, 565, 195, 30e-5p, 374, 19a, 101, 424,
29b,186,141,320,422b,and197insquamouscellcarcinoma
cells, miR-15b, 16, 20a, 20b, 30b, and 224 in carcinoma of
nasopharyngeal epithelial cells, and miR-424 in trophoblasts
[43–45]. There is also evidence that the response to hypoxia
may be cell-speciﬁc. For example, let-7e, 7g and 7i are
hypoxia-inducible in squamous cell carcinoma [44], whereas
let-7a, 7c, 7d, 7e, 7f, and 7g are downregulated by hypoxia
in nasopharyngeal carcinomas [43]. Further proof of cell
speciﬁcity in the response to hypoxia is provided by results
that showed let-7f, 7g, and 7i have contrasting expression
levels in diﬀerent colon and breast cancer cell lines [46].
Most of the hypoxia inducible miRNAs are also over-
expressed in solid tumors suggesting that the induction of
miRNAs in hypoxia initiates a signaling pathway that leads
to tumor survival and/or proliferation [42]. A good example
is glioblastomas, which have a hypoxic microenvironment
[47, 48]. As previously mentioned, miR-21 is overexpressed
in glioblastoma [38, 49]. In addition to its role in ECM
modiﬁcations through the inhibition of TIMP3, this overex-
pressionalsoplaysaroleinapoptosisevasioninglioblastoma
cells, suggesting a role in cell survival. Therefore it is likely
that the hypoxic microenvironment of glioblastomas lead
to overexpression of miR-21, which modulates expression
of transcripts that are needed for the tumors survival. In
another example, colon cancer miR-107 can inhibit p53
regulation of hypoxic signaling and tumor angiogenesis [50].
Another area that needs further investigation in order to
understandhowmiRNAsareregulatingthehypoxicresponse
and its role in cancer is identiﬁcation of the targets of
these regulators. Bioinformatic analysis of predicted targets
suggest that the hypoxic regulated miRNAs may play a role
in regulating apoptosis, cell proliferation, vascularization,
and the response of cancer to chemotherapy. Unfortunately
only a few of the predicted targets have been experimentally
tested (see below). One example that has been tested is
HMGA2 (high-mobility group A2), which has been shown
to play a role in how the tumor responds to chemotherapy.
Expression of HMGA2 is reduced in a hypoxic environment
and it is likely that miR-98, let-7g, 7e, and 7i are at least
partially responsible for this regulation [45]. More recently,
it was shown that vascular endothelial growth factor (VEGF)
expression is mediated by hypoxia-inducible factor HIF-
1 and STAT3 in a miR-20b-dependent manner in MCF-7
breastcancercellsunderconditionsthatmimichypoxia[51].
The role of miR-20b in modulating VEGF expression in an
oxygendependent manner was conﬁrmedin a separate study
[52].
Several studies suggest that miR-210 is key regulator
of the HIF response to hypoxia in cancer (reviewed in
[53]). In one study, the expression of miR-210 and miR-373
were induced in a HIF-1A-dependent manner in a hypoxic
environment [54]. Overexpression of miR-210 suppressed
the abundance of RAD52, which plays a role in homology-
dependent repair. Similarly, overexpression of miR-373
decreased RAD23B, the nucleotide excision repair protein,
and RAD52. Under hypoxic conditions, both RAD52 and
RAD23B are downregulated. There is also evidence that
miR-210 plays a role in mitochondrial dysfunction in some
lung cancers. MiR-210 suppresses the expression of subunit
D of succinate dehydrogenase complex (SDH), one of the
subunits of the electron transport chain complexes I and
II, and thereby activates HIF-1 [55]. In addition, miR-210
most likely decreases the expression of ISCU (iron-sulfur
cluster scaﬀold homolog) and COX10 (cytochrome c oxidase
assembly protein), two key factors of the mitochondria
electron transport chain and the tricarboxylic acid cycle,
during hypoxia [56]. In contrast to the role mir-210 plays
in allowing cells to survive during hypoxia, it also represses
genes expressed under normoxia that are no longer needed
to adapt in a hypoxic environment [57]. Because of its
numerous identiﬁed roles in regulating the hypoxic response
incancer,miR-210maybeaprognosticbiomarkerforseveral
cancers including pancreatic [58] ,h e a da n dn e c k[ 59], and
renal cancer [60].
One question that remains unanswered is whether
hypoxia-inducible factors (HIF), the master regulators of
the response to low oxygen, regulate the expression of the
miRNAs. The HIF transcription factors contain an oxygen-
regulated alpha subunit and a constitutively expressed beta
subunit. Under normoxic conditions, the alpha subunit is
degraded. Under hypoxic conditions, however, the HIF is
stabilized and thus regulates the transcription of numerous
genes including some involved with angiogenesis, glucose
metabolism, and survival, all of which are likely to play a
role in cancer development [61]. Suggestive evidence that
HIF does regulate the transcription of hypoxia-inducible
miRNAs under low oxygen conditions used chromatin
immunoprecipitation assays to show that HIF binds to
the promoters of regulated miRNAs [42]. It is unknown
which factors function in regulating the miRNAs that are
downregulated in hypoxia [46].
Another intriguing potential role for miRNAs in the
microenvironment has recently been revealed. Solid tumors
have an irregular vasculature that creates an environment
that alternates between hypoxia and reoxygenation that most
likely plays an important role in the tumor’s survival. A sub-
population of cancer stem cells was identiﬁed under hypoxic
and reoxygenating cycling conditions that are expected to
function in relapse and metastasis by allowing new tumors
to arise [62]. The expression of miR200c, miR205, and
miR-215 is reduced under these alternating conditions in
stem cells. MiR200c and miR205 were previously shown to
be reduced in cancer stem cells [63]. MiR-215 suppresses
epithelial-mesenchymal transition (EMT) by decreasing the
expression of the mesenchymal transcription factor ZEB2
and increasing the E-cadherin level [64].
In most cases, the downregulation of particular miR-
NAs in regulating the hypoxic response has not yet been
identiﬁed. An exception to this is found in hepatocellular
carcinomatissuewherethefunctionalconsequenceofreduc-
ing miR-29 expression sensitized cells to apoptosis that was
triggered by hypoxia, and thus it is potentially useful as a
cancer therapy [65].6 Molecular Biology International
5. The Need for Further Research in
Understandingthe Role of miRNAs in
the Microenvironment
One of the key issues that need to be addressed in future
studiesishowmiRNAbiogenesisisregulatedinthemicroen-
vironment of cancers. We are just beginning to identify the
regulators of miRNA biogenesis (recently reviewed in [66–
70]).RNApolymeraseII,andinsomecasesRNApolymerase
III, transcribes the primary transcripts (pri-microRNAs)
[71, 72]. The pri-microRNAs also undergo capping, splicing,
and polyadenylation and thus have many potential steps
where regulation of expression might be controlled by
endogenous and exogenous stimuli. It is less likely that
the microRNA biogenesis machinery is responsible for the
diﬀerential expression of miRNAs observed under hypoxic
conditions since the miRNA processing proteins Ago2,
Drosha, Exp5, Dicer, and DP103 expression is unaltered in
hypoxic trophoblasts [45].
Another area where more research is needed is identiﬁca-
tion of the targets of the miRNAs. There are many web sites
available that may be used to predict potential targets of the
miRNAs. It is not unusual to identify hundreds of potential
targets for a particular miRNA. In addition, comparison
of the prediction between various web sites indicates that
there is some, but not necessarily extensive, overlap between
the predicted targets. Thus, it remains unclear which web
sites are the most useful for predicting miRNA targets that
will be experimentally validated. Perhaps a better approach
with regard to studying the targets of the miRNAs is to
identify mRNAs and/or proteins that are dysregulated under
hypoxic conditions. Transcripts that are dysregulated under
low oxygen and have predicted hypoxic regulated miRNA
binding sites are excellent candidates for further testing.
Further investigation is also needed to determine if there
are synergistic eﬀects of miRNAs. In most studies in which
the function of miRNAs is assayed, one miRNA at a time
is either up- or downregulated. This approach will not
allow the investigator to determine if the activity of each
miRNA has any synergistic or inhibitory impact on the other
miRNAs. Further studies are needed in which the expression
of multiple miRNAs is manipulated so that the eﬀects may
be compared to the results obtained from manipulating the
activity of individual miRNAs.
6. Conclusions
In situ carcinomas that remain localized and noninvasive at
the time of diagnosis are associated with positive clinical
outcomes and increased disease-free survival for patients.
Unfortunately, the majority of tumors at the time of
diagnosis are invasive malignant tumors with a portion
of these having metastasized to secondary sites decreasing
patient prognosis and survival. The ability of tumor cells
to accomplish this migration and invasion is dependent
on cross-talk with the surrounding microenvironment. An
understanding of the mechanisms by which tumor cells
communicate with the microenvironment to promote can-
cer growth and metastasis has the promise of providing
innovative avenues of therapeutic intervention. Collectively,
observations that miRNAs act as mediators of heterotypic
signaling in the tumor stroma and ECM as well as inﬂuence
responses to hypoxia provide researchers with a novel target
forsuchtherapies.Theuseofchemopreventativemeasuresto
control the expression of miRNAs in the microenvironment
willbeanimportantapproachtotheglobalcontrolofcancer.
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